Houston, We Have A Winner In CenterPoint Energy
Houston, We Have A Winner In CenterPoint Energy
CenterPoint Energy, Inc. (CNP) Q4 2025 Earnings Call Transcript
CenterPoint Energy, Inc. (CNP) Q4 2025 Earnings Call Transcript
CenterPoint Energy Q4 Earnings Lag Estimates, Revenues Rise Y/Y
CNP posts Q4 EPS miss but lifts 2025 profit, boosts long-term investment plan to $65B and reiterates 2026 growth outlook.
Compared to Estimates, CenterPoint (CNP) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for CenterPoint (CNP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CenterPoint Energy (CNP) Q4 Earnings Miss Estimates
CenterPoint Energy (CNP) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.4 per share a year ago.
CenterPoint Energy (CNP) Reports Next Week: Wall Street Expects Earnings Growth
CenterPoint (CNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Data Center Beneficiaries Raising Dividends Up to 60%
Dividends are on the rise for three stocks that are benefiting significantly from data center demand. Their expertise spans energy generation, server supply, and construction management.
CNP to Benefit From Infrastructure Upgradation & Renewable Expansion
CNP is betting $65B on grid upgrades and renewables as power demand rises, targeting 1,000 MW by 2026 and an 8.86% long-term earnings growth rate.
4 Stocks That Declared Dividend Hikes Amid Ongoing Economic Uncertainty
CNP, VAC, PCG and ZTS raised dividends as tech volatility and economic uncertainty push income-focused investors toward steadier stocks.
5 Stocks Worth Watching on Their Recent Dividend Hikes
PNR, NVT, CNP, VAC and PCG stand out as dividend payers as market volatility persists, with each company recently announcing higher shareholder payouts.
Here's My Prediction For Who Could Acquire Ascendis Pharma
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year, with operating profitability achieved for the quarter. TransCon CNP, targeting achondroplasia, faces a critical FDA PDUFA date on February 28th, with multi-billion-euro TAM potential if approved.
Down 5.3% in 4 Weeks, Here's Why CenterPoint (CNP) Looks Ripe for a Turnaround
CenterPoint (CNP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
